RxDoctor Payments Data

Tracy Valerie Bertiz

Acute Care · New York, NYNPI 1033388111

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,738in general payments, 2019–2025

Across 203 payments — averaging $33.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • Novartis$959
  • AstraZeneca$642
  • Abbott$415
  • Pfizer$335
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$6,736100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,738 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$23,926
EntrestoSacubitril/Valsartan22$18,571
Olmesartan Medoxomil11$893
Atorvastatin Calcium39$580
Rosuvastatin Calcium34$485
Metoprolol Succinate31$385
Ezetimibe14$244
Torsemide16$242
Amlodipine Besylate27$241
Labetalol Hcl12$199
Lisinopril31$182
Carvedilol26$135
Losartan Potassium19$110
Furosemide22$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$335$23,92632 claims
NovartisEntresto$959$18,57122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.

Other acute care in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →